Attention Deficit Hyperactivity Disorder (ADHD)
Conditions
Keywords
ADHD, omega3
Brief summary
Attention deficit hyperactivity disorder (ADHD) is a major problem in children and adolescents. Clinical and biochemical evidence suggests that deficiencies of polyunsaturated fatty acids (PUFA) could be related to ADHD. PUFAs are the major components of brain with important physiologically active functions. Aim: Study the relationship between omega3 blood values and ADHD clinical status. Methods: The investigators will recruit 30 children, who have been diagnosed with ADHD by a child psychiatrist. In addition the investigators will recruit a control group of 30 children without ADHD and related neuropsychiatric syndromes. Blood will be taken from all children. The ADHD children will be asked to consume omega3 capsules for 6 month. After 3 and 6 months, all children will undergo clinical examination and blood tests will be taken for omega3 index analysis. Blind frozen samples of isolated red blood cell (RBC) will be analyzed according to the omega3 index methodology.
Detailed description
Attention deficit hyperactivity disorder (ADHD) is a major problem in children and adolescents. Clinical and biochemical evidence suggests that deficiencies of polyunsaturated fatty acids (PUFA) could be related to ADHD. PUFAs are the major components of brain with important physiologically active functions. Aim: To investigate influence effects of omega3 dietary supplementation on ADHD symptoms and the measured blood values. Methods: The study will be authorized by the Ziv Helsinki Committee and the Ministry of Health. Written Informed consent will obtained from parents. The investigators will recruit 30 children, who have been diagnosed with ADHD by a child psychiatrist. In addition the investigators will recruit a control group of 30 children without ADHD and related neuropsychiatric syndromes. Blood will be taken from all children.
Interventions
PROCEDUREblood test
Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
DIETARY_SUPPLEMENTomega3 capsules
Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
Sponsors
Ayelet Omer Armon
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Years to 14 Years
Healthy volunteers
Yes
Inclusion criteria
\- ADHD group: Children diagnosed with ADHD aged 6-14; children who have not received a dietary supplement of omega3 in the last month Control group inclusion criteria: Children without ADHD and related neuropsychiatric syndromes aged 6-14, Children who have not received a dietary supplement of omega3 in the last month.
Exclusion criteria
\- Children with severe chronic or autoimmune disorders, children who received a dietary supplement of omega3 in the last month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood omega3 | 6 month |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ADHD Symptoms | 6 month | Will be assessed using the ADHD Rating Scale IV (ADHD RS). |
Outcome results
None listed